In vivo staging of regional amyloid deposition

Neurology

Volumn 89, Issue 20, 2017, Pages 2031-2038

  Grothe, Michel J ^a   Barthel, Henryk ^b   Sepulcre, Jorge ^c   Dyrba, Martin ^a   Sabri, Osama ^b   Teipel, Stefan J ^a,d  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; BIOLOGICAL MARKER; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANATOMICAL VARIATION; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; FEMALE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NEUROIMAGING; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSORIMOTOR CORTEX; STAGING; AGING; BRAIN CORTEX; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; METABOLISM; NEOSTRIATUM; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOMARKERS; CEREBRAL CORTEX; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; NEOSTRIATUM; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 85033462055     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004643     Document Type: Article

References (40)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
2. Thal DR, Rub U, Orantes M, Braak H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
3. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
4. 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015;138:1370-1381.
5. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12:295-312.
6. Giannakopoulos P, Hof PR, Vallet PG, Giannakopoulos AS, Charnay Y, Bouras C. Quantitative analysis of neuropathologic changes in the cerebral cortex of centenarians. Prog Neuropsychopharmacol Biol Psychiatry 1995;19: 577-592.
7. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012;72:599-609.
8. Teipel S, Drzezga A, Grothe MJ, et al. Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurol 2015;14:1037-1053.
9. Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement 2015;11:964-974.
10. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275-283.
11. Thal DR, Beach TG, Zanette M, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 2015;11:975-985.
12. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015;138:2020-2033.
13. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
14. Josephs KA, Murray ME, Whitwell JL, et al. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol 2016;131:571-585.
15. Gertz HJ, Xuereb J, Huppert F, et al. Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol 1998;95:154-158.
16. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008;116:1-16.
17. Grothe MJ, Teipel SJ. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. Hum Brain Mapp 2016;37:35-53.
18. Grothe MJ, Heinsen H, Amaro E Jr, Grinberg LT, Teipel SJ. Cognitive correlates of basal forebrain atrophy and associated cortical hypometabolism in mild cognitive impairment. Cereb Cortex 2016;26:2411-2426.
19. Teipel S, Grothe MJ. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl Med Mol Imaging 2016;43:526-536.
20. Teipel SJ, Kurth J, Krause B, Grothe MJ. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment: beyond classical regression. Neuroimage Clin 2015;8:583-593.
21. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-583.
22. Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET: application to amyloid imaging with AV45-PET. Neuroimage 2017;147: 669-677.
23. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968-980.
24. Catafau AM, Bullich S, Seibyl JP, et al. Cerebellar amyloid-beta plaques: how frequent are they, and do they influence 18F-florbetaben SUV ratios? J Nucl Med 2016; 57:1740-1745.
25. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378-384.
26. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70-77.
27. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68:1404-1411.
28. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
29. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74: 826-836.
30. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927-934.
31. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
32. Vlassenko AG, Benzinger TL, Morris JC. PET amyloidbeta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta 2012;1822:370-379.
33. Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 2016;80:247-258.
34. Beach TG, Sue LI, Walker DG, et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis 2012;28:869-876.
35. Annus T, Wilson LR, Hong YT, et al. The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement 2016;12:538-545.
36. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27: 6174-6184.
37. 11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008;131: 1845-1853.
38. Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009;66: 1537-1544.
39. Beach TG, Thal DR, Zanette M, Smith A, Buckley C. Detection of striatal amyloid plaques with [18F]flutemetamol: validation with postmortem histopathology. J Alzheimers Dis 2016;52:863-873.
40. Shah N, Frey KA, Muller ML, et al. Striatal and cortical beta-amyloidopathy and cognition in Parkinson's disease. Mov Disord 2016;31:111-117.